SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-076222
Filing Date
2024-06-21
Accepted
2024-06-21 16:05:32
Documents
12
Period of Report
2024-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20240618.htm   iXBRL 8-K 63926
2 EX-10.1 rare-ex10_1.htm EX-10.1 128132
  Complete submission text file 0000950170-24-076222.txt   325860

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20240618.xsd EX-101.SCH 23897
15 EXTRACTED XBRL INSTANCE DOCUMENT rare-20240618_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 241060163
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)